Key facts
- Notable investors include Regents of the University of California, Innovations for Impact, Michael J. Fox Foundation.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Acurex Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Acurex Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Acurex Biosciences
Operator of a pharmaceutical company intended to halt major neurodegenerative diseases. The company specializes in supporting the impairment of mitophagy, by which cells dispose of dysfunctional mitochondria, which plays a significant role in the pathogenesis of PD and other diseases, enabling medical facilities to identify druggable targets responsible for defects in mitophagy.
- Sector
- Healthcare
- HQ
- San Carlos, CA, United States
- Founded
- 2019
- Employees
- 12
- Website
- acurex.com/
- Ownership
- Privately Held (backing)
Acurex Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Acurex Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Acurex Biosciences in its N-PORT filings yet. We sweep new filings monthly.